Matinas Biopharma Holdings Current Ratio 2012-2019 | MTNB

Matinas Biopharma Holdings current ratio from 2012 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Matinas Biopharma Holdings Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-09-30 $0.03B $0.00B 13.06
2019-06-30 $0.04B $0.00B 10.81
2019-03-31 $0.04B $0.00B 12.81
2018-12-31 $0.01B $0.00B 4.61
2018-09-30 $0.01B $0.00B 2.85
2018-06-30 $0.01B $0.00B 6.27
2018-03-31 $0.01B $0.00B 4.75
2017-12-31 $0.01B $0.00B 4.50
2017-09-30 $0.01B $0.00B 5.40
2017-06-30 $0.01B $0.00B 8.79
2017-03-31 $0.02B $0.00B 8.60
2016-12-31 $0.01B $0.00B 3.16
2016-09-30 $0.01B $0.00B 4.80
2016-06-30 $0.00B $0.00B 0.58
2016-03-31 $0.00B $0.00B 1.45
2015-12-31 $0.00B $0.00B 3.15
2015-09-30 $0.01B $0.00B 5.60
2015-06-30 $0.01B $0.00B 6.06
2015-03-31 $0.01B $0.00B 3.70
2014-12-31 $0.00B $0.00B 2.51
2014-09-30 $0.01B $0.00B 5.01
2014-06-30 $0.01B $0.00B 7.67
2014-03-31 $0.01B $0.00B 12.84
2013-12-31 $0.01B $0.00B 12.72
2013-09-30 $0.01B $0.00B 25.09
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-12-31 $0.00B 0.00
2012-09-30 $0.00B 0.00
2011-12-31 $0.00B $0.00B 1.33
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.298B $0.000B
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.
Stock Name Country Market Cap PE Ratio
Takeda Pharmaceutical (TAK) Japan $62.499B 9.88
Zoetis (ZTS) United States $57.742B 34.54
Astellas Pharma (ALPMY) Japan $32.535B 16.25
Eisai (ESALY) Japan $21.712B 41.87
UCB SA (UCBJF) Belgium $15.658B 0.00
Grifols, S.A (GRFS) Spain $15.559B 20.39
Merck (MKGAF) Germany $14.630B 19.97
Neurocrine Biosciences (NBIX) United States $10.476B 494.57
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Ionis Pharmaceuticals (IONS) United States $8.896B 18.02
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.638B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $8.562B 10.94
Catalent (CTLT) United States $7.617B 30.99
IPSEN SA ADR (IPSEY) France $7.404B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $6.486B 98.22
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.263B 0.00
Orion OYJ (ORINY) Finland $5.849B 30.12
STADA ARZNEIMI (STDAF) Germany $5.375B 0.00
Hypermarcas (HYPMY) Brazil $4.849B 17.43
FibroGen (FGEN) United States $4.167B 122.46
Nektar Therapeutics (NKTR) United States $4.066B 0.00
United Therapeutics (UTHR) United States $3.995B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.733B 13.64
Evotec AG (EVTCY) Germany $3.406B 55.73
Sage Therapeutics (SAGE) United States $3.247B 0.00
PTC Therapeutics (PTCT) United States $2.972B 0.00
ArQule (ARQL) United States $2.379B 0.00
Xencor (XNCR) United States $2.350B 71.43
Heron Therapeutics (HRTX) United States $2.307B 0.00
Portola Pharmaceuticals (PTLA) United States $2.198B 0.00
Zogenix (ZGNX) United States $2.072B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.934B 61.65
Tilray (TLRY) Canada $1.930B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.901B 56.24
ChemoCentryx (CCXI) United States $1.720B 0.00
USANA Health Sciences (USNA) United States $1.645B 17.55
Corcept Therapeutics (CORT) United States $1.571B 19.10
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.488B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.257B 28.70
CLINIGEN GP (CLIGF) United Kingdom $1.245B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.198B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.162B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.065B 7.27
Endo (ENDP) Ireland $1.041B 1.91
Radius Health (RDUS) United States $1.034B 0.00
Karyopharm Therapeutics (KPTI) United States $0.998B 0.00
Aerie Pharmaceuticals (AERI) United States $0.975B 0.00
Flexion Therapeutics (FLXN) United States $0.770B 0.00
Akebia Therapeutics (AKBA) United States $0.707B 0.00
Collegium Pharmaceutical (COLL) United States $0.703B 0.00
TherapeuticsMD (TXMD) United States $0.656B 0.00
ImmunoGen (IMGN) United States $0.569B 0.00
Translate Bio (TBIO) United States $0.521B 0.00
Dermira (DERM) United States $0.496B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.493B 0.00
Organogenesis Holdings (ORGO) United States $0.469B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.464B 56.25
Molecular Templates (MTEM) United States $0.462B 0.00
Ardelyx (ARDX) United States $0.449B 0.00
Harpoon Therapeutics (HARP) United States $0.439B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.437B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.423B 18.23
Indivior (INVVY) United States $0.399B 1.44
BioCryst Pharmaceuticals (BCRX) United States $0.387B 0.00
Recro Pharma (REPH) United States $0.387B 0.00
Lannett Co Inc (LCI) United States $0.370B 4.31
DURECT (DRRX) United States $0.367B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.362B 0.00
OptiNose (OPTN) United States $0.359B 0.00
Innate Pharma SA (IPHYF) France $0.358B 0.00
Siga Technologies (SIGA) United States $0.353B 8.07
Concordia (CXRXF) Canada $0.322B 0.00
Rafael Holdings (RFL) United States $0.319B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.316B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.275B 0.00
KalVista Pharmaceuticals (KALV) United States $0.272B 0.00
Jounce Therapeutics (JNCE) United States $0.270B 3.61
GlycoMimetics (GLYC) United States $0.261B 0.00
Calithera Biosciences (CALA) United States $0.247B 0.00
Xeris Pharmaceuticals (XERS) United States $0.239B 0.00
Ocular Therapeutix (OCUL) United States $0.194B 0.00
Aquestive Therapeutics (AQST) United States $0.194B 0.00
Concert Pharmaceuticals (CNCE) United States $0.188B 0.00
Nature's Sunshine Products (NATR) United States $0.187B 32.23
Foamix Pharmaceuticals (FOMX) Israel $0.182B 0.00
Taiwan Liposome (TLC) Taiwan $0.167B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.150B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.145B 0.00
IMV INC (IMV) Canada $0.143B 0.00
MEI Pharma (MEIP) United States $0.141B 0.00
Redhill Biopharma (RDHL) Israel $0.138B 0.00
CannTrust Holdings (CTST) Canada $0.129B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.126B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
CV Sciences (CVSI) United States $0.091B 0.00
Champions Oncology (CSBR) United States $0.091B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.088B 0.00
MediWound (MDWD) Israel $0.083B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.079B 23.68
Capnia (SLNO) United States $0.079B 0.00
Otonomy (OTIC) United States $0.078B 0.00
Neos Therapeutics (NEOS) United States $0.075B 0.00
Aclaris Therapeutics (ACRS) United States $0.074B 0.00
PolarityTE (PTE) United States $0.074B 0.00
Infinity Pharmaceuticals (INFI) United States $0.072B 0.00
Cardiome Pharma (CORV) Canada $0.071B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.067B 0.00
Pharmaxis (PXSLY) Australia $0.065B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.064B 0.00
RENEURON GP (RNUGF) United Kingdom $0.062B 0.00
Nivalis Therapeutics (ALPN) United States $0.060B 0.00
Novan (NOVN) United States $0.060B 0.00
AgeX Therapeutics (AGE) United States $0.058B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.057B 0.00
Genocea Biosciences (GNCA) United States $0.056B 0.00
SCYNEXIS (SCYX) United States $0.056B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.056B 0.00
Iterum Therapeutics (ITRM) Ireland $0.056B 0.00
Natural Alternatives (NAII) United States $0.055B 13.80
Medicure (MCUJF) Canada $0.055B 0.00
ElectroCore (ECOR) United States $0.052B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.051B 0.00
CTI BioPharma (CTIC) United States $0.051B 0.00
IntelGenx Technologies (IGXT) Canada $0.051B 0.00
Mast Therapeutics (SVRA) United States $0.048B 0.00
IsoRay (ISR) United States $0.046B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.040B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.040B 0.00
Forward Pharma (FWP) Denmark $0.038B 0.00
Opexa Therapeutics (ACER) United States $0.038B 0.00
Mannatechorporated (MTEX) United States $0.038B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.033B 0.00
India Globalization Capital (IGC) United States $0.029B 0.00
PharmAthene (ALT) United States $0.028B 0.00
Jaguar Animal Health (JAGX) United States $0.028B 0.00
Shineco (TYHT) China $0.028B 0.00
Biomerica (BMRA) United States $0.028B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.026B 0.00
Melinta Therapeutics (MLNT) United States $0.023B 0.00
ProPhase Labs (PRPH) United States $0.023B 0.00
Bio-Path Holdings (BPTH) United States $0.022B 0.00
China SXT Pharmaceuticals (SXTC) China $0.020B 0.00
Heat Biologics (HTBX) United States $0.016B 0.00
Flex Pharma (SLRX) United States $0.016B 0.00
Regulus Therapeutics (RGLS) United States $0.016B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.016B 0.00
VAXART, INC (VXRT) United States $0.016B 0.00
Vical (BBI) United States $0.015B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Lipocine (LPCN) United States $0.010B 0.00
Achieve Life Sciences (ACHV) United States $0.009B 0.00
HANCOCK JAFFE (HJLI) United States $0.008B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Can-Fite Biopharma (CANF) Israel $0.005B 0.00
Hemispherx BioPharma (AIM) United States $0.003B 0.00
Onconova Therapeutics (ONTX) United States $0.002B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.001B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00